Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address:
Tel:
Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries.
Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America.
Business results and main therapeutic areas
In 2009, total sales reached € 3.2 billion, with an adjusted EBITDA of € 1.1 billion. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines.
Nycomed’s differentiated portfolio of branded medicines is focused on gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Global R&D and Manufacturing presence
Research and Development is conducted at three sites in Europe and one in India. New products are sourced from our own internal Discovery organisation and in-licensed from external companies such as small biotechs. Establishing long-term partnerships is a cornerstone of Nycomed´s growth strategy.
Nycomed has 16 manufacturing sites: 5 centres of competence in Europe for global products as well as 11 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed’s biggest single market.
Nycomed provides branded medicines for hospitals, specialists and general practitioners, as well as over-the-counter (OTC) medicines. Our strong global brands complement product portfolios adapted to local preferences. Around the world, our guiding principle is to develop “medicines that matter”
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here